AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm Oct 1 (Reuters) - AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million. Cheplapharm will pay AstraZeneca about $243 million for Losec, a proton pump inhibitor developed by the British drugmaker. The sale also includes milestone payments of up to $33 million in 2021 and 2022 contingent on sales. The global commercial rights being sold to Cheplapharm, for Losec (omeprazole) and its associated brands, excludes rights in China, Japan, the United States and Mexico, AstraZeneca said. AstraZeneca said it will still make and supply Losec and its associated medicines and sell the medicine in markets where it still holds the rights. In 2018, Losec sales in the countries covered under this agreement with Cheplapharm were $98 million, the British drugmaker said. The divestment includes
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer [Yahoo! Finance]Yahoo! Finance
- AstraZeneca PLC (NASDAQ: AZN) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.MarketBeat
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research [Yahoo! Finance]Yahoo! Finance
- Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]Yahoo! Finance
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/8/24 - Form 6-K
- AZN's page on the SEC website